Welcome to our dedicated page for PTC THERAPEUTICS SEC filings (Ticker: PTCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on PTC THERAPEUTICS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into PTC THERAPEUTICS's regulatory disclosures and financial reporting.
A shareholder filed a Form 144 notice to sell 2,314 shares of common stock through Fidelity Brokerage Services LLC, with an aggregate market value of $180,314.42. The shares are part of an outstanding base of 80,288,305 shares and are expected to be sold on or about January 9, 2026 on the NASDAQ exchange.
The seller acquired these 2,314 shares on January 7, 2026 via restricted stock vesting from the issuer as compensation. The filing also lists prior open-market sales over the past three months by Mark Boulding, including 4,879 shares sold on January 7, 2026 for $377,839.55, alongside several other transactions with six‑figure gross proceeds.
Form 144 discloses a planned sale of 2,746 common shares through Fidelity Brokerage Services LLC, with an aggregate market value of 213,888.74. These shares relate to an issuer with 80,288,305 common shares outstanding and are expected to be sold on or about 01/09/2026 on the NASDAQ exchange.
The securities to be sold were acquired on 01/07/2026 via restricted stock vesting from the issuer as compensation, in the same amount of 2,746 shares. The notice also lists earlier sales over the prior three months by Eric Pauwels, including 40,290 common shares sold on 12/17/2025 for gross proceeds of 3,038,755.33, along with smaller transactions on several subsequent dates in December 2025 and January 2026.
PTC Therapeutics senior executive Christine Marie Utter reported automatic stock sales linked to restricted stock unit (RSU) vesting. As SVP and Chief Accounting Officer, she sold 1,381 shares of common stock at $76.95 on January 6, 2026 and 1,235 shares at $77.45 on January 7, 2026.
According to the footnotes, both sales were made under irrevocable “sell to cover” elections entered into when the RSU grants were accepted, solely to satisfy tax withholding obligations on the vesting of 3,500 RSUs from separate 14,000‑share grants. After these transactions, she directly owns 73,727 shares of PTC Therapeutics common stock.
PTC Therapeutics’ chief financial officer, Pierre Gravier, reported an automatic sale of company stock tied to RSU vesting. On 01/06/2026, he sold 2,139 shares of PTC Therapeutics common stock at a price of $76.95 per share. The filing states these shares were sold pursuant to an irrevocable “sell to cover” election entered into when he accepted the grant, in order to satisfy tax withholding obligations on the vesting of 5,625 restricted stock units (RSUs) from a January 3, 2025 grant of 22,500 RSUs. Following this tax-related sale, he beneficially owned 90,310 shares of PTC Therapeutics common stock directly.
PTC Therapeutics, Inc. (PTCT) chief business officer Eric Pauwels reported automatic sales of common stock to cover tax withholding from restricted stock unit (RSU) vesting. On January 6, 2026, he sold 1,789 shares of common stock at $76.95 per share. On January 7, 2026, he sold an additional 1,352 shares at $77.48 per share. Both transactions were executed under an irrevocable sell-to-cover election entered into when the RSU grants were accepted and were made to satisfy tax withholding obligations tied to the vesting of RSUs granted in January 2023 and January 2025. After these transactions, Pauwels directly beneficially owned 87,489 shares of PTC Therapeutics common stock.
PTC Therapeutics, Inc. (PTCT) CEO Matthew B. Klein reported automatic sales of common stock tied to RSU vesting. On January 6, 2026, 5,149 shares of common stock were sold at $76.95 per share, and on January 7, 2026, 3,016 shares were sold at $77.48 per share. Both transactions are coded as sales and are reported as directly owned shares.
According to the footnotes, these sales were made under irrevocable "sell to cover" elections to satisfy tax withholding obligations arising from the vesting of 17,500 RSUs from a January 3, 2025 grant of 70,000 RSUs and 6,500 RSUs from a January 5, 2023 grant of 26,000 RSUs. After these transactions, Klein directly beneficially owns 396,967 shares of PTC Therapeutics common stock.
PTC Therapeutics executive Golden Lee Scott, EVP & Chief Medical Officer, reported automatic sales of company stock tied to RSU vesting. On January 6, 2026, 1,340 shares of PTC Therapeutics common stock were sold at $76.95 per share in a transaction marked as a sale, leaving 93,936 shares beneficially owned directly. On January 7, 2026, a further 642 shares were sold at $77.48 per share, resulting in direct beneficial ownership of 93,294 shares.
According to the footnotes, both transactions represent shares automatically sold under an irrevocable "sell to cover" election made when the RSU grants were accepted, in order to satisfy tax withholding obligations upon vesting of 5,000 RSUs from a January 3, 2025 grant of 20,000 RSUs and 2,666 RSUs from a January 5, 2023 grant of 10,640 RSUs.
PTC Therapeutics executive Mark Elliott Boulding, Executive VP and Chief Legal Officer, reported a series of stock option exercises and related share sales in PTCT common stock. On January 7, 2026 he exercised options for 3,376 shares at an exercise price of $38.10 per share and sold multiple small blocks of common stock at weighted average prices generally between $76.95 and $78.98 per share. Some sales on January 6–7, 2026 were automatic “sell-to-cover” transactions to satisfy tax withholding tied to vesting of restricted stock units, and other trades were carried out under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, he directly owned 117,659 shares of PTC Therapeutics common stock.
PTC Therapeutics officer Neil Gregory Almstead reported automatic sales of company stock tied to restricted stock unit (RSU) vesting. On January 6, 2026, he sold 1,279 shares of common stock at $76.95 per share directly and 54 shares at $76.95 held indirectly through his spouse. On January 7, 2026, he sold an additional 1,026 shares at $77.48 directly and 52 shares at $77.48 through his spouse.
According to the footnotes, all of these sales were made under irrevocable “sell to cover” elections to satisfy tax withholding obligations arising from the vesting of RSUs granted in 2023 and 2025. Following these transactions, Almstead beneficially owns 116,077 shares directly and 6,850 shares indirectly through his spouse.
A shareholder has filed a notice of proposed sale of 866 shares of common stock, to be sold through Fidelity Brokerage Services LLC on or about 01/08/2026 on the NASDAQ. The filing lists an aggregate market value of 66,204.92 for these shares and notes that 80,288,305 shares of the same class were outstanding at the time. The 866 shares were acquired on 01/07/2026 through restricted stock vesting from the issuer as compensation.
The notice also reports that the same seller disposed of 1,340 shares for 103,109.78 on 01/06/2026 and 642 shares for 49,744.60 on 01/07/2026. By signing, the seller represents that they are not aware of any undisclosed material adverse information about the issuer’s operations.